Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
JAK
fedratinib
myelofibrosis
platelets
thrombocytopaenia
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
01
04
2022
received:
29
11
2021
accepted:
06
04
2022
pubmed:
28
4
2022
medline:
19
7
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Fedratinib, an oral Janus kinase-2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 10
Identifiants
pubmed: 35476316
doi: 10.1111/bjh.18207
pmc: PMC9541243
doi:
Substances chimiques
Nitriles
0
Protein Kinase Inhibitors
0
Pyrrolidines
0
Sulfonamides
0
fedratinib
6L1XP550I6
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 1
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-327Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Br J Haematol. 2020 Jun;189(5):888-903
pubmed: 32017044
Lancet Haematol. 2018 Feb;5(2):e73-e81
pubmed: 29275119
Expert Rev Hematol. 2013 Oct;6(5):511-23
pubmed: 24083419
Am J Hematol. 2020 Jun;95(6):594-603
pubmed: 32129512
Br J Haematol. 2022 Jul;198(2):317-327
pubmed: 35476316
Int J Gen Med. 2014 Jan 29;7:89-101
pubmed: 24501543
J Hematol Oncol. 2018 Aug 7;11(1):101
pubmed: 30086777
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
Semin Hematol. 2009 Jan;46(1 Suppl 2):S37-43
pubmed: 19245933
Lancet Haematol. 2017 Jul;4(7):e317-e324
pubmed: 28602585
Best Pract Res Clin Haematol. 2006;19(3):495-517
pubmed: 16781486
Blood Cancer J. 2015 Aug 07;5:e335
pubmed: 26252788
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Cancer. 2008 Jun 15;112(12):2726-32
pubmed: 18404742
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
J Clin Oncol. 2017 Dec 1;35(34):3844-3850
pubmed: 28930494
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Hematol Oncol. 2013 Oct 29;6(1):81
pubmed: 24283202
Br J Haematol. 2021 Oct;195(2):244-248
pubmed: 34331348
Blood. 2017 Feb 9;129(6):667-679
pubmed: 28028029
JAMA Oncol. 2018 May 1;4(5):652-659
pubmed: 29522138
Lancet Haematol. 2017 May;4(5):e225-e236
pubmed: 28336242
Haematologica. 2019 May;104(5):947-954
pubmed: 30442723
Leuk Res. 2009 Sep;33(9):1199-203
pubmed: 19250674
Cancer Discov. 2015 Mar;5(3):316-31
pubmed: 25572172
Eur J Haematol. 2010 Feb 1;84(2):105-8
pubmed: 19895568
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Oncogene. 2013 May 23;32(21):2601-13
pubmed: 22869151
Am J Hematol. 2021 Jan;96(1):145-162
pubmed: 33197049